Sanofi revises annual sales growth expectations on strong Dupixent demand
It had previously said it expects annual sales to grow by mid-to-high single-digit percentage at constant currency rates.
The drugmaker also confirmed that it expects earnings to grow at a low double-digit percentage this year.
Sanofi has significantly amped up its R&D expenditure in recent years, a move that led it to abandon its long-term margin targets in 2023. This shift underscores its focus to capitalize on the success of its blockbuster drug Dupixent as it builds its next wave of growth drivers.
Sales of its asthma drug Dupixent rose 21.1% to 3.83 billion euros ($4.38 billion), compared to 3.74 billion euros expected on average by analysts in a company-provided poll.
Quarterly business operating income, excluding one-off items, rose by 3.3% to 2.46 billion euros, below the average analyst estimate of 2.57 billion euros in a poll posted on the company's website.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
11 hours ago
- Business Recorder
European shares log biggest daily drop after US tariffs hike
FRANKFURT: European stocks logged their biggest one-day drop in over three months on Friday, at the end of a busy week as investors grappled with the repercussions of fresh US levies on dozens of countries, including a 39% tariff on Switzerland. Investors shunned riskier equities globally as Trump continued his tariff blitz, announcing steep levies on exports from dozens of trading partners including Canada, Brazil, India and Taiwan with countries not listed subject to a base 10% rate ahead of a Friday trade deal deadline. Healthcare stocks lost 1% after US President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies, including Novo Nordisk and Sanofi, outlining how they should slash US prescription drug prices. The sector was already singed this week by Novo Nordisk's profit warning. The Denmark-listed Wegovy-maker shed 1.8% and logged its steepest weekly decline on record. 'We saw during the week that companies like Novo Nordisk had different issues. European pharma is very close to bottoming and that's why it didn't react to the uncertainty around tariffs and policy,' Anthi Tsouvali, a multi-asset strategist at UBS Global Wealth Management said. 'Europe is an export market... if we see heightened tariffs all over the world and trade being subdued, then that will have an impact on European companies regardless.' The pan-European STOXX 600 index slid 1.9% and marked its biggest one-week drop since early April when Trump unveiled his tariffs on world economies. The euro STOXX volatility index jumped 4.25 points to its highest in over one-month. The STOXX index has lost over 5% from its March peak, after coming within 2% of that level earlier this week, dragged down by a record plunge in Novo Nordisk shares, and as investors assess the implications of the US-EU trade deal. Markets in Switzerland were shut for a holiday, but UK-listed Watches of Switzerland declined 6.8%, while a US-listed exchange traded fund tracking the country's equities slid to a more than three-month low and was last down 1.2%. Most regional bourses were in the red, with Germany's blue-chip DAX down 2.7%, while Denmark's OMXC fell 1.8% to a nearly two-year low. Banks, that had rallied earlier in the week, were down 3.4% and were the top sectoral underperformer as they notched their biggest one-day drop since early April.
Business Recorder
a day ago
- Business Recorder
European stocks end at over one-week low
FRANKFURT: European shares closed at a more than one-week low on Thursday, as investors were disappointed by a series of corporate reports from the likes of Sanofi and Ferrari, while beverage makers slid as they were faced with a 15% US tariff. Earnings were in full swing in Europe this week as traders gauged the impact US tariffs were likely to have on corporate performance for the rest of the year. The pan-European STOXX 600 index finished 0.75% lower, with Italian stocks underperforming the most in major markets with a 1.5% decline. Italian luxury carmaker Ferrari slid 11.7% - marking its biggest one-day drop since its listing nine years ago. The stock also weighed on the broader STOXX automobile sector which was down nearly 4%. The sports-car maker maintained its annual forecasts and said that it will reduce the price compensation it introduced earlier on some cars sold in the US, once the US-EU trade deal was effective. However, analysts mulled if the company can sustain its high profitability. Drugmaker Sanofi also dropped 7.8% after reporting lower-than-expected earnings, but said that the impact from US tariffs could be manageable. 'When we think about sectors like automotives, pharma and consumer discretionary names — the risk is these sectors are particularly vulnerable to US tariffs,' said Craig Cameron, portfolio manager and research analyst at Templeton Global Investments. 'So we're consciously deciding to lean away from them and focus more on utilities, industrials, and financials that are largely domestically driven and insulated from tariffs.'
Business Recorder
2 days ago
- Business Recorder
Sanofi revises annual sales growth expectations on strong Dupixent demand
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer treatments. It had previously said it expects annual sales to grow by mid-to-high single-digit percentage at constant currency rates. The drugmaker also confirmed that it expects earnings to grow at a low double-digit percentage this year. Sanofi has significantly amped up its R&D expenditure in recent years, a move that led it to abandon its long-term margin targets in 2023. This shift underscores its focus to capitalize on the success of its blockbuster drug Dupixent as it builds its next wave of growth drivers. Sales of its asthma drug Dupixent rose 21.1% to 3.83 billion euros ($4.38 billion), compared to 3.74 billion euros expected on average by analysts in a company-provided poll. Quarterly business operating income, excluding one-off items, rose by 3.3% to 2.46 billion euros, below the average analyst estimate of 2.57 billion euros in a poll posted on the company's website.
